Abstract
AbstractSome patients treated with dupilumab for atopic dermatitis (AD) develop resistance on their face, despite achieving good response on other body parts. The pathomechanisms of dupilumab‐resistant facial erythema (DRFE) are unclear and its treatment is challenging. We report a case of DRFE resistant to topical corticosteroids and delgocitinib that was successfully treated with tacrolimus ointment. Tacrolimus ointment was not effective for his facial AD before dupilumab initiation but was effective for DRFE, suggesting that DRFE has a different pathomechanism from AD.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
